Moderna Narrows Q2 Loss but Norovirus Vaccine Trial Hits Snag
Moderna reported a narrower second-quarter net loss of $782 million, or $1.97 per share, compared to a loss of $825 million, or $2.13 per share, in the same period last year. The results beat analyst expectations, as FactSet-polled analysts had projected a per-share loss of $2.03. However, the company's norovirus vaccine trial encountered a setback, though details of the trial's failure were not specified in the source. The financial improvement comes amid ongoing challenges in the biotech sector, with Moderna continuing to focus on its vaccine pipeline. The company's stock is traded under the ticker MRNA. The Wall Street Journal provided the analyst consensus figures.
Key facts
- Moderna's Q2 net loss narrowed to $782 million from $825 million year-over-year.
- Loss per share was $1.97, beating the FactSet consensus of $2.03.
- The norovirus vaccine trial hit a wall, but specifics are not provided.
- The company's stock ticker is MRNA.
- Analyst projections were sourced from The Wall Street Journal.
Entities
Institutions
- Moderna
- FactSet
- The Wall Street Journal
Sources
- Quartz —